Acute toxicity study of tilmicosin-loaded hydrogenated castor oil-solid lipid nanoparticles

Particle and Fibre Toxicology

Volumn 8, Issue , 2011, Pages

  Xie, Shuyu ^a   Wang, Fenghua ^a   Wang, Yan ^a   Zhu, Luyan ^a   Dong, Zhao ^a   Wang, Xiaofang ^a   Li, Xihe ^b   Zhou, WenZhong ^a  

^a CHINA AGRICULTURAL UNIVERSITY   (China)

^b Inner Mongolia Univ College of Life Sciences   (China)

Author keywords

Acute toxicity; Hydrogenated castor oil (hco); Solid lipid nanoparticles (sln); Tilmicosin

Indexed keywords

CASTOR OIL; SOLID LIPID NANOPARTICLE; TILMICOSIN; ANTIINFECTIVE AGENT; DRUG CARRIER; DRUG DERIVATIVE; LIPID; NANOPARTICLE; TYLOSIN;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; BLOOD CHEMISTRY; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FLUID INTAKE; FOOD INTAKE; GROWTH RATE; HEART; HISTOPATHOLOGY; LD 50; LETHARGY; LIVER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; TOXICITY TESTING; ANIMAL; BODY WEIGHT; CHEMISTRY; DRINKING; DRUG EFFECT; EATING; HEART MUSCLE; HYDROGENATION; INSTITUTE FOR CANCER RESEARCH MOUSE; LONGEVITY; PARTICLE SIZE; PATHOLOGY;

ANIMALIA; MUS;

ANIMALS; ANTI-BACTERIAL AGENTS; BODY WEIGHT; CASTOR OIL; DRINKING; DRUG CARRIERS; EATING; FEMALE; HEART; HYDROGENATION; LETHAL DOSE 50; LIPIDS; LIVER; LONGEVITY; MALE; MICE; MICE, INBRED ICR; MYOCARDIUM; NANOPARTICLES; PARTICLE SIZE; SPLEEN; TOXICITY TESTS, ACUTE; TYLOSIN;

EID: 81255209595     PISSN: None     EISSN: 17438977     Source Type: Journal    
DOI: 10.1186/1743-8977-8-33     Document Type: Article

References (31)

1. Ziv G, ShemTov M, Glickman A, Winkler M, Saran A. Tilmicosin antibacterial activity and pharmacokinetics in cows. J Vet Pharmacol Ther 1995, 18:340-345.
2. Ramadan A. Pharmacokinetics of tilmicosin in serum and milk of goats. Res Vet Sci 1997, 62:48-50.
3. Nickerson SC, Owens WE, Fox LK, Scheifinger CC, Shryock TR, Spike TE. Comparison of tilmicosin and cephapirin as therapeutics for Staphylococcus aureus mastitis at dry-off. J Dairy Sci 1999, 82:696-703.
4. Owens WE, Nickerson SC, Ray CH. Efficacy of parenterally or intramammarily administered tilmicosin or ceftiofur against Staphylococcus mastitis during lactation. J Dairy Sci 1999, 82:645-647.
5. Wang XF, Zhang SL, Zhu LY, Xie SY, Dong Z, Wang Y, Zhou WZ. Enhancement of antibacterial activity of tilmicosin against Staphylococcus aureus by solid lipid nanoparticles in vitro and in vivo. VET J 2011,
6. Van Donkersgoed J, Dubeski PL, VanderKop M, Aalhus JL, Bygrove S, Starr WN. The effect of animal health products on the formation of injection site lesions in subprimals of experimentally injected beef calves. Can Vet J 2000, 41:617-622.
7. Clark C, Dowling PM, Ross S, Woodbury M, Boison JO. Pharmacokinetics of tilmicosin in equine tissues and plasma. J Vet Pharmacol Ther 2008, 31:66-70.
8. Yapar K, Kapt A, Karapehlivan M. effects of different doses of tilmicosin on some biochemical parameters and antioxidant status in serum and cardiac tissues in mice. Vet Inst Pulawy 2006, 50:605-608.
9. Han C, Qi CM, Zhao BK, Cao J, Xie SY, Wang SL, Zhou WZ. Hydrogenated castor oil nanoparticles as carriers for the subcutaneous administration of tilmicosin: in vitro and in vivo studies. J Vet Pharmacol Ther 2009, 32:116-123.
10. Weyhers H, Ehlers S, Hahn H, Souto EB, Müller RH. Solid Lipid Nanoparticles (SLN)- Effects of lipid composition on in vitro degradation and in vivo toxicity. Pharmazie 2006, 61:539-544.
11. Schöler N, Hahn H, Müller RH, Liesenfeld O. Effect of lipid matrix and size of solid lipid nanoparticles (SLN) on the viability and cytokine production of macrophages. Int J Pharm 2002, 231:167-176.
12. Olbricha C, Gessner A, Schröder W, Kayser O, Müller RH. Lipid-drug conjugate nanoparticles of the hydrophilic drug diminazene--cytotoxicity testing and mouse serum adsorption. J Control Release 2004, 96:425-435.
13. Medina C, Santos-Martinez MJ, Radomski A, Corrigan OI, Radomski MW. Nanoparticles: pharmacological and toxicological significance. Brit J Pharmacol 2007, 150:552-558.
14. Sagstad A, Sanden M, Krogaahl A, Bakke-Mackllep AM, FrØYstad M, Hemre GI. Organs development, gene expression and health of Atlantic salmon (Salmao Salar L.) fed genetically modified soybeans compared to the near-isogenic non-modified parental line. Aquacult Nutr 2008, 14:556-572.
15. Chen Z, Meng H, Xing GM, Chen CY, Zhao YL, Jia G, Wang TC, Yuan H, Ye C, Zhao F, Chai ZF, Zhu CF, Fang XH, Ma BC, Wan LJ. Acute toxicological effects of copper nanoparticles in vivo. Toxicol Lett 2006, 163:109-120.
16. Dhana lekshmi UM, Poovi G, Kishore N, Neelakanta Reddy P. In vitro characterization and in vivo toxicity study of repaglinide loaded poly (methyl methacrylate) nanoparticles. Int J Pharm 2010, 396:194-203.
17. Buttarello M, Plebani M. Automated Blood Cell Counts. Am J Clin Pathol 2008 130:104-116.
18. AM, Sabino EC, Sampaio L, Neto CA, Schreiber G B, Chamone DDAF, Dorlhiac-Llacer PE. Anemia screening in potential female blood donors: comparison of two different quantitative methods. Transfusion 2009, 49:662-668.
19. LD50 Test Policy, Federal Register: Food and Drug Administration [FDA]. 1988, (11):39650-3965153.
20. Zbinden G, Flury-Roversi M. Significance of the LD50 test for the toxicological evaluation of chemical substances. ArchToxicol 1981, 47:77-99.
21. Acute Oral Toxicity-Acute Toxic Class Method Organization for Economic Cooperation and Development (OECD) Guidelines for Testing of Chemicals Guideline. 2001, 423. Acute Oral Toxicity-Acute Toxic Class Method.
22. Jordan WH, Byra RA, Cochrane RL, Hanasono GK, Hoyt JA, Main BW, Meyehoff RD, Sarazan RD. A review of the toxicology of the antibiotic Micotil 300. Vet Hum Toxicol 1993, 35:151-158.
23. DOT Department of Transportation Code of Federal Regulations. Title 49, part 173132 1997, US Government Printing Office, Washington, DC, DOT Department of Transportation.
24. Watson WC, Gordon RS. Studies on the digestion, absorption and metabolism of castor oil. Biochem Pharmacol 1962, 11:229-236.
25. DeMerlis CC, Schoneker DR. Review of the oral toxicity of polyvinyl alcohol (PVA). Food Chem Toxicol 2003, 41:319-326.
26. Blasi P, Giovagnoli S, Schoubben A, Ricci M, Rossi C. Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Deliver Rev 2007, 59:454-477.
27. Weyhers H, Mehnert W, Hahn H, Müller RH. Solid lipid nanoparticles-determination of in vivo toxicity. Proc First World Meeting APGI/APV, Budapest 1995, 489-490.
28. Woodman DD. Assessment of hepatic function and damage in animal species. A review of the current approach of the academic, governmental and industrial institutions represented by the Animal Clinical Chemistry Association. J Appl Toxicol 1988, 8:249-254.
29. Hermansky SJ, Neptun DA, Weaver EV, Ballantyne B. Clinical Pathology Changes Related to Cutaneous Irritation in the Fischer 344 Rat and New Zealand White Rabbit. Cutaneous and ocular toxicology 1995, 14:219-236.
30. McGuigan MA. Human exposures to tilmicosin. Vet Human Toxicol 1994, 36:306-308.
31. Yazar E, Altunok V, Elmas M, Tras B, Bas AL, Özdemir V. Effect of tilmicosin on cardiac muscle and serum creatine kinases activities and serum total protein level in healthy male Balb/C mice. Revue Méd Vét 2001, 152:881-883.